Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.27
OTCPK:GLAXF's Cash-to-Debt is ranked lower than
81% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.09 vs. OTCPK:GLAXF: 0.27 )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:GLAXF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.47 Max: 7.44
Current: 0.27
0.02
7.44
Equity-to-Asset 0.02
OTCPK:GLAXF's Equity-to-Asset is ranked lower than
97% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. OTCPK:GLAXF: 0.02 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:GLAXF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.02  Med: 0.29 Max: 0.67
Current: 0.02
0.02
0.67
Interest Coverage 3.71
OTCPK:GLAXF's Interest Coverage is ranked lower than
85% of the 635 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 105.95 vs. OTCPK:GLAXF: 3.71 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:GLAXF' s Interest Coverage Range Over the Past 10 Years
Min: 3.71  Med: 9.73 Max: 17.51
Current: 3.71
3.71
17.51
Piotroski F-Score: 5
Altman Z-Score: 1.32
Beneish M-Score: -2.74
WACC vs ROIC
7.59%
8.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 9.32
OTCPK:GLAXF's Operating Margin % is ranked higher than
53% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.42 vs. OTCPK:GLAXF: 9.32 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:GLAXF' s Operating Margin % Range Over the Past 10 Years
Min: 9.32  Med: 28.07 Max: 43.15
Current: 9.32
9.32
43.15
Net Margin % 3.27
OTCPK:GLAXF's Net Margin % is ranked lower than
62% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.16 vs. OTCPK:GLAXF: 3.27 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:GLAXF' s Net Margin % Range Over the Past 10 Years
Min: 3.27  Med: 19.28 Max: 35.2
Current: 3.27
3.27
35.2
ROE % 46.73
OTCPK:GLAXF's ROE % is ranked higher than
96% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. OTCPK:GLAXF: 46.73 )
Ranked among companies with meaningful ROE % only.
OTCPK:GLAXF' s ROE % Range Over the Past 10 Years
Min: 17.3  Med: 58.32 Max: 179.63
Current: 46.73
17.3
179.63
ROA % 1.61
OTCPK:GLAXF's ROA % is ranked lower than
62% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. OTCPK:GLAXF: 1.61 )
Ranked among companies with meaningful ROA % only.
OTCPK:GLAXF' s ROA % Range Over the Past 10 Years
Min: 1.61  Med: 12.82 Max: 18.45
Current: 1.61
1.61
18.45
ROC (Joel Greenblatt) % 25.36
OTCPK:GLAXF's ROC (Joel Greenblatt) % is ranked higher than
67% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.40 vs. OTCPK:GLAXF: 25.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:GLAXF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 25.36  Med: 82.61 Max: 120.14
Current: 25.36
25.36
120.14
3-Year Revenue Growth Rate 1.80
OTCPK:GLAXF's 3-Year Revenue Growth Rate is ranked lower than
65% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. OTCPK:GLAXF: 1.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OTCPK:GLAXF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -7.7  Med: 4.8 Max: 18.9
Current: 1.8
-7.7
18.9
3-Year EBITDA Growth Rate -20.50
OTCPK:GLAXF's 3-Year EBITDA Growth Rate is ranked lower than
87% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. OTCPK:GLAXF: -20.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OTCPK:GLAXF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -20.5  Med: 7.9 Max: 21.7
Current: -20.5
-20.5
21.7
3-Year EPS without NRI Growth Rate -44.80
OTCPK:GLAXF's 3-Year EPS without NRI Growth Rate is ranked lower than
94% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. OTCPK:GLAXF: -44.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OTCPK:GLAXF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44.8  Med: 7.4 Max: 51.3
Current: -44.8
-44.8
51.3
GuruFocus has detected 5 Warning Signs with GlaxoSmithKline PLC $OTCPK:GLAXF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:GLAXF's 10-Y Financials

Financials (Next Earnings Date: 2017-04-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with GLAXF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:ABBV, NYSE:SNY, OTCPK:BAYZF, NYSE:LLY, NYSE:BMY, NYSE:AZN, NYSE:MRK, OTCPK:NVSEF, OTCPK:SZUKF, OTCPK:ALPMF, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSNKY, NYSE:PFE, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:PTKFY, OTCPK:SNPHF, OTCPK:GWPRF, NAS:HCM » details
Traded in other countries:GSK.Argentina, GS7.Germany, GSK N.Mexico, OXGSK.Switzerland, GSK.UK, GSK.USA,
Headquarter Location:UK
GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by market capitalization. The company wields its might across multiple therapeutic classes, including respiratory and antiviral, as well as vaccines and healthcare-related consumer products.

Ratios

vs
industry
vs
history
PE Ratio 83.96
GLAXF's PE Ratio is ranked lower than
86% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.48 vs. GLAXF: 83.96 )
Ranked among companies with meaningful PE Ratio only.
GLAXF' s PE Ratio Range Over the Past 10 Years
Min: 6.35  Med: 14.69 Max: 99999999.99
Current: 83.96
6.35
99999999.99
Forward PE Ratio 14.77
GLAXF's Forward PE Ratio is ranked higher than
99% of the 202 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.39 vs. GLAXF: 14.77 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 83.96
GLAXF's PE Ratio without NRI is ranked lower than
87% of the 544 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.85 vs. GLAXF: 83.96 )
Ranked among companies with meaningful PE Ratio without NRI only.
GLAXF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.38  Med: 14.64 Max: 284.83
Current: 83.96
6.38
284.83
Price-to-Owner-Earnings 13.90
GLAXF's Price-to-Owner-Earnings is ranked higher than
81% of the 293 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.45 vs. GLAXF: 13.90 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GLAXF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.75  Med: 15.67 Max: 129.65
Current: 13.9
4.75
129.65
PB Ratio 76.33
GLAXF's PB Ratio is ranked lower than
99% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.03 vs. GLAXF: 76.33 )
Ranked among companies with meaningful PB Ratio only.
GLAXF' s PB Ratio Range Over the Past 10 Years
Min: 5.48  Med: 9.27 Max: 610.36
Current: 76.33
5.48
610.36
PS Ratio 2.80
GLAXF's PS Ratio is ranked higher than
51% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. GLAXF: 2.80 )
Ranked among companies with meaningful PS Ratio only.
GLAXF' s PS Ratio Range Over the Past 10 Years
Min: 1.94  Med: 2.78 Max: 3.83
Current: 2.8
1.94
3.83
Price-to-Free-Cash-Flow 18.88
GLAXF's Price-to-Free-Cash-Flow is ranked higher than
59% of the 226 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.83 vs. GLAXF: 18.88 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GLAXF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.24  Med: 17.46 Max: 135.68
Current: 18.88
8.24
135.68
Price-to-Operating-Cash-Flow 12.03
GLAXF's Price-to-Operating-Cash-Flow is ranked higher than
65% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.62 vs. GLAXF: 12.03 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GLAXF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.61  Med: 11.97 Max: 27.31
Current: 12.03
6.61
27.31
EV-to-EBIT 39.14
GLAXF's EV-to-EBIT is ranked higher than
89% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.99 vs. GLAXF: 39.14 )
Ranked among companies with meaningful EV-to-EBIT only.
GLAXF' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.3  Med: 10.6 Max: 72.6
Current: 39.14
6.3
72.6
EV-to-EBITDA 23.42
GLAXF's EV-to-EBITDA is ranked higher than
95% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.26 vs. GLAXF: 23.42 )
Ranked among companies with meaningful EV-to-EBITDA only.
GLAXF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.6  Med: 9.1 Max: 35.2
Current: 23.42
5.6
35.2
Shiller PE Ratio 16.86
GLAXF's Shiller PE Ratio is ranked higher than
88% of the 161 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.67 vs. GLAXF: 16.86 )
Ranked among companies with meaningful Shiller PE Ratio only.
GLAXF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 11.71  Med: 15.12 Max: 22
Current: 16.86
11.71
22
Current Ratio 0.88
GLAXF's Current Ratio is ranked lower than
91% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.55 vs. GLAXF: 0.88 )
Ranked among companies with meaningful Current Ratio only.
GLAXF' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 1.29 Max: 2.64
Current: 0.88
0.88
2.64
Quick Ratio 0.61
GLAXF's Quick Ratio is ranked lower than
91% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.85 vs. GLAXF: 0.61 )
Ranked among companies with meaningful Quick Ratio only.
GLAXF' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.03 Max: 2.24
Current: 0.61
0.61
2.24
Days Inventory 202.91
GLAXF's Days Inventory is ranked lower than
83% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.29 vs. GLAXF: 202.91 )
Ranked among companies with meaningful Days Inventory only.
GLAXF' s Days Inventory Range Over the Past 10 Years
Min: 167.28  Med: 192.3 Max: 202.91
Current: 202.91
167.28
202.91
Days Sales Outstanding 60.40
GLAXF's Days Sales Outstanding is ranked higher than
63% of the 636 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.05 vs. GLAXF: 60.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
GLAXF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 54.62  Med: 59.8 Max: 93.9
Current: 60.4
54.62
93.9
Days Payable 141.29
GLAXF's Days Payable is ranked higher than
82% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.53 vs. GLAXF: 141.29 )
Ranked among companies with meaningful Days Payable only.
GLAXF' s Days Payable Range Over the Past 10 Years
Min: 116.45  Med: 140.18 Max: 345.65
Current: 141.29
116.45
345.65

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 5.00
GLAXF's Dividend Yield % is ranked higher than
97% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. GLAXF: 5.00 )
Ranked among companies with meaningful Dividend Yield % only.
GLAXF' s Dividend Yield % Range Over the Past 10 Years
Min: 2.92  Med: 5.13 Max: 6.24
Current: 5
2.92
6.24
Dividend Payout Ratio 4.30
GLAXF's Dividend Payout Ratio is ranked higher than
64% of the 410 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. GLAXF: 4.30 )
Ranked among companies with meaningful Dividend Payout Ratio only.
GLAXF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.46  Med: 0.75 Max: 4.3
Current: 4.3
0.46
4.3
3-Year Dividend Growth Rate -1.30
GLAXF's 3-Year Dividend Growth Rate is ranked lower than
68% of the 285 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. GLAXF: -1.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
GLAXF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5 Max: 62.4
Current: -1.3
0
62.4
Forward Dividend Yield % 4.96
GLAXF's Forward Dividend Yield % is ranked higher than
97% of the 658 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.59 vs. GLAXF: 4.96 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 5.16
GLAXF's 5-Year Yield-on-Cost % is ranked higher than
88% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.09 vs. GLAXF: 5.16 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
GLAXF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.04  Med: 5.34 Max: 6.49
Current: 5.16
3.04
6.49
3-Year Average Share Buyback Ratio -3.40
GLAXF's 3-Year Average Share Buyback Ratio is ranked higher than
55% of the 442 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. GLAXF: -3.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GLAXF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.6  Med: -0.6 Max: 4.7
Current: -3.4
-26.6
4.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.23
GLAXF's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
53% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. GLAXF: 2.23 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GLAXF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.07  Med: 2.29 Max: 77.2
Current: 2.23
1.07
77.2
Price-to-Median-PS-Value 1.01
GLAXF's Price-to-Median-PS-Value is ranked higher than
57% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. GLAXF: 1.01 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GLAXF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.81  Med: 1.19 Max: 3.36
Current: 1.01
0.81
3.36
Earnings Yield (Greenblatt) % 2.57
GLAXF's Earnings Yield (Greenblatt) % is ranked higher than
92% of the 1046 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.36 vs. GLAXF: 2.57 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GLAXF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.4  Med: 9.4 Max: 15.8
Current: 2.57
1.4
15.8
Forward Rate of Return (Yacktman) % -7.63
GLAXF's Forward Rate of Return (Yacktman) % is ranked lower than
84% of the 369 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.72 vs. GLAXF: -7.63 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
GLAXF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -8  Med: 8.8 Max: 18.2
Current: -7.63
-8
18.2

More Statistics

Revenue (TTM) (Mil) $37,533
EPS (TTM) $ 0.24
Beta1.21
Short Percentage of Float0.00%
52-Week Range $18.16 - 22.98
Shares Outstanding (Mil)5,368.32

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 37,062 38,161 39,451
EPS ($) 1.36 1.38 1.52
EPS without NRI ($) 1.36 1.38 1.52
EPS Growth Rate
(Future 3Y To 5Y Estimate)
3.97%
Dividends per Share ($) 1.01 1.01 1.01
» More Articles for OTCPK:GLAXF

Headlines

Articles On GuruFocus.com
Pernix: An Investor's Rationale to Staying Long Mar 23 2017 
Jeff Auxier Reduces, Exits Multiple Positions in 4th Quarter Mar 22 2017 
Gilead Sciences Raises Dividend by Double Digits Feb 22 2017 
If You Want Yield, Look to the UK Feb 19 2017 
Flood of News Presents Buying Opportunity Jan 17 2017 
Gilead Sciences Must Answer to Investors After a Disappointing 2016 Jan 05 2017 
GlaxoSmithKline, Vodafone Hit 3-Year Low Prices Dec 24 2016 
Asset Sales, New Projects Fuel 6.7% Yield Dec 07 2016 
Robust Pipeline Supports 5.5% Dividend Yield Dec 05 2016 
Jeff Auxier Curbs Multiple Positions in 3rd Quarter Dec 01 2016 

More From Other Websites
New GlaxoSmithKline CEO wants fewer, bigger new drug launches Apr 26 2017
Analyst Ratings and Recommendations for GlaxoSmithKline Apr 26 2017
Glaxo meets 1Q profit forecasts Apr 26 2017
Ionis Pharmaceuticals: Big Data Coming Soon Apr 26 2017
Glaxo Stock Slumps as Investors Eye Advair Generics Apr 26 2017
Glaxo (GSK) Beats Earnings and Revenues in Q1 Apr 26 2017
GlaxoSmithKline’s 1Q17 Estimates: Consumer Healthcare Apr 26 2017
GlaxoSmithKline Beats Q1 Estimates, Keeps Full Year Targets In Place Apr 26 2017
GSK warns of impact from generic drugs after solid Q1 Apr 26 2017
[$$] GlaxoSmithKline Net Income Boosted by Strong Sales, Weak Pound Apr 26 2017
GlaxoSmithKline’s 1Q17 Estimates: Vaccines Business Apr 26 2017
Glaxo's New CEO Walmsley Pledges to Make Drugs the Priority Apr 26 2017
Glaxo Profit Jumps 31% as Sales of HIV, Lung Drugs Increase Apr 26 2017
Weak sterling boosts GlaxSmithKline as new CEO takes over Apr 26 2017
[$$] GlaxoSmithKline 1Q Results Expected to Get Boost From Weak Pound Apr 25 2017
GlaxoSmithKline’s 1Q17 Estimates: Revenues Expected to Grow Apr 25 2017
GlaxoSmithKline’s 1Q17 Earnings: Analysts’ Estimates Apr 25 2017
Drug Stocks Q1 Earnings Releases on Apr 26: AMGN, GSK & More Apr 25 2017
First malaria vaccine to be tested in Africa, with boost from Lexington's Agenus Apr 24 2017
3 Dividend Stocks That Retirees Should Avoid Apr 22 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)